Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients

Authors not listed

Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 2025

Abstract

Aging is often accompanied by the reduction and weakening of muscle mass, a condition defined as sarcopenia. According to the most recent criteria from the European Working Group on Sarcopenia in Older People, sarcopenia is considered probable when low muscle strength is documented in the patient. The diagnosis of sarcopenia is then confirmed by the presence of reduced muscle mass quantity or quality; it is classified as severe when low muscle strength, reduced muscle quantity and quality, and poor physical performance are all present. According to a recent systematic review of 130 studies, sarcopenia is estimated to affect 10-16% of older adults worldwide. Low muscle strength and rapid atrophy may also result from prolonged immobility, which is an undesirable consequence of hospitalization after illness or injury. Approximately 65% of elderly patients experience reduced ambulatory function due to hospitalization, and between 30% and 55% report a decline in daily living activities. It has been reported that healthy older adults lose 1 kg (approximately 6%) of lean tissue in the lower limbs after 10 days of bed rest, with a corresponding 16% decline in isokinetic strength of the knee extensors. Muscle atrophy during bed rest is primarily attributed to a marked decrease in skeletal muscle protein synthesis rates, although an accelerated rate of muscle protein degradation compared to synthesis cannot be ruled out. The onset of sarcopenia is further promoted by inflammation, immunosenescence, anabolic resistance, and increased oxidative stress. Since proper diet, physical activity, and supplementation are currently considered the fundamental pillars for the treatment and prevention of sarcopenia, the identification of a specific food for special medical purposes (AFMS) capable of slowing the progression of sarcopenia is extremely important. Treating sarcopenia also means preventing the associated negative outcomes, including lower overall and progression-free survival rates, postoperative complications, extended hospital stays in patients with various medical conditions, as well as falls and fractures, metabolic disorders, cognitive decline, and mortality in the general population.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Anonymous. (2025). Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients. <em>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</em>. https://clinicaltrials.gov/study/NCT06801808
Vancouver
Anonymous. Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients. Fondazione Policlinico Universitario Agostino Gemelli IRCCS. 2025.
BibTeX
@misc{anon2025Evalua, title = {Evaluation of HMB Supplementation on Motor Performance in Sarcopenic Patients}, author = {Anonymous}, journal = {Fondazione Policlinico Universitario Agostino Gemelli IRCCS}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings